Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Landgren Website

C. Ola Landgren, M.D., Ph.D.

Selected Publications

1)  Drahos J, Vanwormer JJ, Greenlee RT, Landgren O, Koshiol J.
Accuracy of ICD-9-CM codes in identifying infections of pneumonia and herpes simplex virus in administrative data.
Ann Epidemiol. [Epub ahead of print], 2013.
[Journal]
2)  Kristinsson SY, Eloranta S, Dickman PW, Andersson TM, Turesson I, Landgren O, Björkholm M.
Patterns of survival in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005.
Am. J. Hematol. 88: 60-5, 2013.
[Journal]
3)  Engels EA, Savoldo B, Pfeiffer RM, Costello R, Zingone A, Heslop HE, Landgren O.
Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients.
Transplantation. 95: 519-26, 2013.
[Journal]
4)  Hillengass J, Landgren O.
Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging 'early myeloma'.
Leuk. Lymphoma. [Epub ahead of print], 2013.
[Journal]
5)  Lamy L, Ngo VN, Emre NC, Shaffer AL, Yang Y, Tian E, Nair V, Kruhlak MJ, Zingone A, Landgren O, Staudt LM.
Control of Autophagic Cell Death by Caspase-10 in Multiple Myeloma.
Cancer Cell. [Epub ahead of print], 2013.
[Journal]
6)  Manasanch EE, Kristinsson SY, Landgren O.
Etiology of Waldenström Macroglobulinemia: Genetic Factors and Immune-related Conditions.
Clin Lymphoma Myeloma Leuk. [Epub ahead of print], 2013.
[Journal]
7)  Cherry BM, Korde N, Kwok M, Roschewski M, Landgren O.
Evolving therapeutic paradigms for multiple myeloma: back to the future.
Leuk. Lymphoma. 54: 451-63, 2013.
[Journal]
8)  Cherry BM, Costello R, Zingone A, Burris J, Korde N, Manasanch E, Kwok M, Annunziata C, Roschewski MJ, Engels EA, Landgren O.
Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age.
Am. J. Hematol. 88: 89-92, 2013.
[Journal]
9)  Wu SP, Minter A, Costello R, Zingone A, Lee CK, Au WY, Landgren O.
MGUS prevalence in an ethnically Chinese population in Hong Kong.
Blood. 121: 2363-4, 2013.
[Journal]
10)  Cherry BM, Korde N, Kwok M, Manasanch EE, Bhutani M, Mulquin M, Zuchlinski D, Yancey MA, Maric I, Calvo KR, Braylan R, Stetler-Stevenson M, Yuan C, Tembhare P, Zingone A, Costello R, Roschewski MJ, Landgren O.
Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study.
Leuk. Lymphoma. [Epub ahead of print], 2013.
[Journal]
11)  Fernández de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, Hajek R, San Miguel JF, Sezer O, Sonneveld P, Kumar SK, Mahindra A, Comenzo R, Palumbo A, Mazumber A, Anderson KC, Richardson PG, Badros AZ, Caers J, Cavo M, Leleu X, Dimopoulos MA, Chim CS, Schots R, Noeul A, Fantl D, Mellqvist UH, Landgren O, Chanan-Khan A, Moreau P, Fonseca R, Merlini G, Lahuerta JJ, Bladé J, Orlowski RZ, Shah JJ.
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.
Leukemia. 27: 780-91, 2013.
[Journal]
12)  Shiels MS, Landgren O, Goedert JJ, Engels EA.
Reply to bibas et Al.
Clin. Infect. Dis. 56: 1350, 2013.
[Journal]
13)  Katzmann JA, Clark R, Kyle RA, Larson DR, Therneau TM, Melton LJ, Benson JT, Colby CL, Dispenzieri A, Landgren O, Kumar S, Bradwell AR, Cerhan JR, Rajkumar SV.
Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.
Leukemia. 27: 208-12, 2013.
[Journal]
14)  Kristinsson SY, Björkholm M, Landgren O.
Survival in Monoclonal Gammopathy of Undetermined Significance and Waldenström Macroglobulinemia.
Clin Lymphoma Myeloma Leuk. [Epub ahead of print], 2013.
[Journal]
15)  Hofmann JN, Liao LM, Pollak MN, Wang Y, Pfeiffer RM, Baris D, Andreotti G, Lan Q, Landgren O, Rothman N, Purdue MP.
A prospective study of circulating adipokine levels and risk of multiple myeloma.
Blood. 120: 4418-20, 2012.
[Journal]
16)  Tembhare P, Yuan C, Korde N, Maric I, Landgren O.
Antigenic drift in relapsed extramedullary multiple myeloma: plasma cells without CD38 expression.
Leuk. Lymphoma. 53: 721-4, 2012.
[Journal]
17)  Chang CM, Landgren O, Koshiol J, Björkholm M, Löve TJ, Kristinsson SY.
Borrelia and subsequent risk of solid tumors and hematologic malignancies in Sweden.
Int J Cancer. [Epub ahead of print], 2012.
[Journal]
18)  Kwok M, Korde N, Landgren O.
Bortezomib to treat the TEMPI syndrome.
N. Engl. J. Med. 366: 1843-5, 2012.
[Journal]
19)  Engels EA, Preiksaitis J, Zingone A, Landgren O.
Circulating antibody free light chains and risk of posttransplant lymphoproliferative disorder.
Am. J. Transplant. 12: 1268-74, 2012.
[Journal]
20)  Goldin LR, Kristinsson SY, Liang XS, Derolf AR, Landgren O, Björkholm M.
Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes.
J. Clin. Oncol. 30: 179-83, 2012.
[Journal]
21)  Kristinsson SY, Goldin LR, Turesson I, Björkholm M, Landgren O.
Familial aggregation of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia with solid tumors and myeloid malignancies.
Acta Haematol. 127: 173-7, 2012.
[Journal]
22)  Kristinsson SY, Goldin L, Turesson I, Hultcrantz M, Björkholm M, Landgren O.
Family history of venous thromboembolism is associated with increased risk for thrombosis in multiple myeloma: a population-based study.
J. Thromb. Haemost. 10: 962-4, 2012.
[Journal]
23)  Shiels MS, Landgren O, Costello R, Zingone A, Goedert JJ, Engels EA.
Free light chains and the risk of AIDS-defining opportunistic infections in HIV-infected individuals.
Clin. Infect. Dis. 55: e103-8, 2012.
[Journal]
24)  Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel J, Barlogie B, Morgan G, Sonneveld P, Spencer A, Andersen KC, Facon T, Stewart KA, Einsele H, Mateos MV, Wijermans P, Waage A, Beksac M, Richardson PG, Hulin C, Niesvizky R, Lokhorst H, Landgren O, Bergsagel PL, Orlowski R, Hinke A, Cavo M, Attal M.
IMWG consensus on maintenance therapy in multiple myeloma.
Blood. 119: 3003-15, 2012.
[Journal]
25)  Tadmor T, Liphshitz I, Aviv A, Landgren O, Barchana M, Polliack A.
Increased incidence of chronic lymphocytic leukaemia and lymphomas in patients with Merkel cell carcinoma - a population based study of 335 cases with neuroendocrine skin tumour.
Br. J. Haematol. 157: 457-62, 2012.
[Journal]
26)  Kristinsson SY, Tang M, Pfeiffer RM, Björkholm M, Goldin LR, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O.
Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study.
Haematologica. 97: 854-8, 2012.
[Journal]
27)  Landgren O, Staudt L.
MYD88 L265P somatic mutation in IgM MGUS.
N. Engl. J. Med. 367: 2255-6; author reply 2256-7, 2012.
[Journal]
28)  Lidén Y, Olofsson N, Landgren O, Johansson E.
Pain and anxiety during bone marrow aspiration/biopsy: Comparison of ratings among patients versus health-care professionals.
Eur J Oncol Nurs. 16: 323-9, 2012.
[Journal]
29)  Hultcrantz M, Kristinsson SY, Andersson TM, Landgren O, Eloranta S, Derolf AR, Dickman PW, Björkholm M.
Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.
J. Clin. Oncol. 30: 2995-3001, 2012.
[Journal]
30)  Landgren O, Ma W, Kyle RA, Rajkumar SV, Korde N, Albitar M.
Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma.
Leukemia. 26: 844-5, 2012.
[Journal]
31)  Birmann BM, Neuhouser ML, Rosner B, Albanes D, Buring JE, Giles GG, Lan Q, Lee IM, Purdue MP, Rothman N, Severi G, Yuan JM, Anderson KC, Pollak M, Rifai N, Hartge P, Landgren O, Lessin L, Virtamo J, Wallace RB, Manson JE, Colditz GA.
Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium.
Blood. 120: 4929-37, 2012.
[Journal]
32)  Sjöberg J, Halthur C, Kristinsson SY, Landgren O, Nygell UA, Dickman PW, Björkholm M.
Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009.
Blood. 119: 990-6, 2012.
[Journal]
33)  Chang CM, Landgren O, Koshiol J, Björkholm M, Löve TJ, Kristinsson SY.
Re: Risk of malignancy associated with Lyme disease: Still up in the air.
International journal of cancer. Journal international du cancer. 2012.
[Journal]
34)  Thomas A, Mailankody S, Korde N, Kristinsson SY, Turesson I, Landgren O.
Second malignancies after multiple myeloma: from 1960s to 2010s.
Blood. 119: 2731-7, 2012.
[Journal]
35)  Manasanch EE, Freeman AF, Pittaluga S, Costello R, Holland SM, Landgren O.
Serum free light chains as predictors of lymphomagenesis in patients with autosomal dominant hyper-immunoglobulin E syndrome (Job"s syndrome).
Leuk. Lymphoma. 2012.
[Journal]
36)  Kurdziel KA, Shih JH, Apolo AB, Lindenberg L, Mena E, McKinney YY, Adler SS, Turkbey B, Dahut W, Gulley JL, Madan RA, Landgren O, Choyke PL.
The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology.
J. Nucl. Med. 53: 1175-84, 2012.
[Journal]
37)  Kristinsson SY, Landgren O.
Thromboprophylaxis in multiple myeloma: is the evidence there?.
Expert Rev Anticancer Ther. 12: 291-4, 2012.
[Journal]
38)  Kristinsson SY, Pfeiffer RM, Bjorkholm M, Schulman S, Landgren O.
Thrombosis is associated with inferior survival in multiple myeloma.
Haematologica. 2012.
[Journal]
39)  Landgren O, Korde N.
Treating myeloma: the future is already here!.
Blood. 120: 1754-6, 2012.
[Journal]
40)  Törner A, Dickman P, Duberg AS, Kristinsson S, Landgren O, Björkholm M, Svensson Å.
A method to visualize and adjust for selection bias in prevalent cohort studies.
Am. J. Epidemiol. 174: 969-76, 2011.
[Journal]
41)  Gadalla SM, Rajan A, Pfeiffer R, Kristinsson SY, Björkholm M, Landgren O, Giaccone G.
A population-based assessment of mortality and morbidity patterns among patients with thymoma.
Int. J. Cancer. 128: 2688-94, 2011.
[Journal]
42)  Landgren O, Polliack A, Tadmor T.
Associations between multiple myeloma and other malignancies.
Leuk. Lymphoma. 52: 161-2, 2011.
[Journal]
43)  Morton LM, Landgren O.
Associations between non-Hodgkin lymphoma and renal cell carcinoma.
Leukemia & lymphoma. 2011.
[Journal]
44)  Landgren AM, Landgren O, Gridley G, Dores GM, Linet MS, Morton LM.
Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans.
Cancer. 117: 1163-71, 2011.
[Journal]
45)  Auner HW, Pavlu J, Szydlo R, Giles C, Kanfer E, Macdonald D, Marin D, Milojkovic D, Rezvani K, Goldman JM, Apperley JF, Landgren O, Rahemtulla A.
Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system.
Br. J. Haematol. 2011.
[Journal]
46)  Minter AR, Simpson H, Weiss BM, Landgren O.
Bone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: pathogenesis, interventions, and future opportunities.
Semin. Hematol. 48: 55-65, 2011.
[Journal]
47)  Kristinsson SY, Minter AR, Korde N, Tan E, Landgren O.
Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management.
Expert Rev. Mol. Diagn. 11: 593-603, 2011.
[Journal]
48)  Gadalla SM, Lund M, Pfeiffer RM, Gørtz S, Mueller CM, Moxley RT, Kristinsson SY, Björkholm M, Shebl FM, Hilbert JE, Landgren O, Wohlfahrt J, Melbye M, Greene MH.
Cancer risk among patients with myotonic muscular dystrophy.
JAMA. 306: 2480-6, 2011.
[Journal]
49)  Kristinsson SY, Björkholm M, Hultcrantz M, Derolf AR, Landgren O, Goldin LR.
Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes.
J. Clin. Oncol. 29: 2897-903, 2011.
[Journal]
50)  Anderson LA, Moore SC, Gridley G, Stone BJ, Landgren O.
Concomitant and antecedent deep venous thrombosis and cancer survival in male US veterans.
Leuk. Lymphoma. 52: 764-70, 2011.
[Journal]
51)  Tan E, Weiss BM, Mena E, Korde N, Choyke PL, Landgren O.
Current and future imaging modalities for multiple myeloma and its precursor states.
Leuk. Lymphoma. 52: 1630-40, 2011.
[Journal]
52)  Landgren O, Rajkumar SV.
Development of early treatment strategies for high-risk myeloma precursor disease in the future.
Semin. Hematol. 48: 66-72, 2011.
[Journal]
53)  Landgren O, Kyle RA, Rajkumar SV.
From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention.
Clin. Cancer Res. 17: 1243-52, 2011.
[Journal]
54)  Buadi F, Hsing AW, Katzmann JA, Pfeiffer RM, Waxman A, Yeboah ED, Biritwum RB, Tettey Y, Adjei A, Chu LW, DeMarzo A, Netto GJ, Dispenzieri A, Kyle RA, Rajkumar SV, Landgren O.
High prevalence of polyclonal hypergamma-globulinemia in adult males in Ghana, Africa.
Am. J. Hematol. 86: 554-8, 2011.
[Journal]
55)  Kristinsson SY, Björkholm M, Schulman S, Landgren O.
Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance.
Semin. Hematol. 48: 46-54, 2011.
[Journal]
56)  Shebl FM, Yu K, Landgren O, Goedert JJ, Rabkin CS.
Increased Levels of Circulating Cytokines with HIV-Related Immunosuppression.
AIDS Res. Hum. Retroviruses. 2011.
[Journal]
57)  Goldin LR, Landgren O, Kristinsson SY, Björkholm M, Paltiel O.
Infection in infancy and subsequent risk of developing lymphoma in children and young adults.
Blood. 117: 1670-2, 2011.
[Journal]
58)  Mena E, Choyke P, Tan E, Landgren O, Kurdziel K.
Molecular imaging in myeloma precursor disease.
Semin. Hematol. 48: 22-31, 2011.
[Journal]
59)  Korde N, Kristinsson SY, Landgren O.
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies.
Blood. 117: 5573-81, 2011.
[Journal]
60)  Landgren O, Korde N.
Multiple myeloma precursor disease: current clinical and epidemiological insights and future opportunities.
Oncology (Williston Park, N.Y.). 25: 589-90, 2011.
[Journal]
61)  Landgren O.
Multiple myeloma precursor disease: current clinical dilemma and future opportunities.
Semin. Hematol. 48: 1-3, 2011.
[Journal]
62)  Landgren O, Thomas A, Mailankody S.
Myeloma and second primary cancers.
N. Engl. J. Med. 365: 2241-2, 2011.
[Journal]
63)  Weiss BM, Minter A, Abadie J, Howard R, Ascencao J, Schechter GP, Kuehl M, Landgren O.
Patterns of monoclonal immunoglobulins and serum free light chains are significantly different in black compared to white monoclonal gammopathy of undetermined significance (MGUS) patients.
Am. J. Hematol. 86: 475-8, 2011.
[Journal]
64)  Lindqvist EK, Goldin LR, Landgren O, Blimark C, Mellqvist UH, Turesson I, Wahlin A, Björkholm M, Kristinsson SY.
Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study.
Blood. 118: 6284-91, 2011.
[Journal]
65)  Hutchison CA, Landgren O.
Polyclonal Immunoglobulin Free Light Chains as a Potential Biomarker of Immune Stimulation and Inflammation.
Clinical chemistry. 2011.
[Journal]
66)  Koshiol J, Lam TK, Gridley G, Check D, Brown LM, Landgren O.
Racial differences in chronic immune stimulatory conditions and risk of non-Hodgkin's lymphoma in veterans from the United States.
J. Clin. Oncol. 29: 378-85, 2011.
[Journal]
67)  Mailankody S, Pfeiffer RM, Kristinsson SY, Korde N, Bjorkholm M, Goldin LR, Turesson I, Landgren O.
Risk of acute myeloid leukemia and myelodysplastic syndromes following multiple myeloma and its precursor disease (MGUS).
Blood. 2011.
[Journal]
68)  Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, Leleu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG, Abildgaard N, Abonour R, Alexanian R, Alsina M, Anderson KC, Attal M, Avet-Loiseau H, Badros A, Baris D, Barlogie B, Bataille R, Beksaç M, Belch A, Ben-Yehuda D, Bensinger B, Leif Bergsagel P, Bird J, Bladé J, Boccadoro M, Cavo M, Chanan-Khan A, Ming Chen W, Child T, Chim J, Chng WJ, Comenzo R, Crowley J, Dalton W, Davies F, de Souza C, Delforge M, Dimopoulos M, Dispenzieri A, Drach J, Drake M, Durie BG, Einsele H, Facon T, Fantl D, Fermand JP, Fonseca R, Gahrton G, García-Sanz R, Gasparetto C, Gertz M, Gibson J, Giralt S, Goldschmidt H, Greipp P, Hajek R, Hardan I, Hari P, Harousseau JL, Hata H, Hattori Y, Heffner T, Ho J, Hungria V, Ida S, Jacobs P, Jagannath S, Johnsen H, Jian H, Joshua D, Jurczyszyn A, Kawano M, Kröger N, Kumar S, Kyle RA, Lacy M, Lahuerta JJ, Landgren O, Laubach J, Lee JH, Leleu X, Lentzsch S, Lokhorst H, Lonial S, Ludwig H, Maiolino A, Mateos M, Mehta J, Mellqvist UH, Merlini G, Mikhael J, Morales AR, Moreau P, Morgan G, Nari H, Munshi N, Niesvizky R, Nouel A, Novis Y, Orlowski R, Palumbo A, Pavlovsky S, Pilarski L, Powles R, Raje N, Vincent Rajkumar S, Reece D, Reiman T, Richardson PG, Roodman D, Rosiñol L, Miguel JS, Sezer O, Shah JJ, Shaughnessy J, Shimizu K, Shustik C, Siegel D, Singhal S, Sonneveld P, Spencer A, Stadtmauer E, Stewart K, Terpos E, Tosi P, Tricot G, Turesson I, Van Camp B, Van Ness B, Van Riet I, Broek IV, Vanderkerken K, Vescio R, Vesole D, Waage A, Wang M, Weber D, Westin J, Wheatley K, Zonder J.
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2011.
[Journal]
69)  Calvo KR, Landgren O, Roccaro AM, Ghobrial IM.
Role of microRNAs from monoclonal gammopathy of undetermined significance to multiple myeloma.
Semin. Hematol. 48: 39-45, 2011.
[Journal]
70)  Björkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sjöberg J, Andersson T, Höglund M, Richter J, Landgren O, Kristinsson SY, Dickman PW.
Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008.
J. Clin. Oncol. 29: 2514-20, 2011.
[Journal]
71)  Landgren O.
Sun, mother of life, prevents cancer.
Blood. 118: 1431-2, 2011.
[Journal]
72)  Björkholm M, Derolf AR, Hultcrantz M, Kristinsson SY, Ekstrand C, Goldin LR, Andreasson B, Birgegård G, Linder O, Malm C, Markevärn B, Nilsson L, Samuelsson J, Granath F, Landgren O.
Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.
J. Clin. Oncol. 29: 2410-5, 2011.
[Journal]
73)  Kristinsson SY, Landgren O.
What causes Waldenström's macroglobulinemia: genetic or immune-related factors, or a combination?.
Clin Lymphoma Myeloma Leuk. 11: 85-7, 2011.
[Journal]
74)  Yancey MA, Waxman AJ, Landgren O.
A case study progression to multiple myeloma.
Clin J Oncol Nurs. 14: 419-22, 2010.
[Journal]
75)  Kristinsson SY, Pfeiffer RM, Björkholm M, Goldin LR, Schulman S, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O.
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study.
Blood. 115: 4991-8, 2010.
[Journal]
76)  Kristinsson SY, Landgren O, Samuelsson J, Björkholm M, Goldin LR.
Autoimmunity and the risk of myeloproliferative neoplasms.
Haematologica. 95: 1216-20, 2010.
[Journal]
77)  Balakumaran A, Robey PG, Fedarko N, Landgren O.
Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis.
Expert Rev. Mol. Diagn. 10: 465-80, 2010.
[Journal]
78)  Landgren O, Goedert JJ, Rabkin CS, Wilson WH, Dunleavy K, Kyle RA, Katzmann JA, Rajkumar SV, Engels EA.
Circulating serum free light chains as predictive markers of AIDS-related lymphoma.
J. Clin. Oncol. 28: 773-9, 2010.
[Journal]
79)  Rawstron AC, Shanafelt T, Lanasa MC, Landgren O, Hanson C, Orfao A, Hillmen P, Ghia P.
Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL).
Cytometry B Clin Cytom. 78 Suppl 1: S19-23, 2010.
[Journal]
80)  Caporaso NE, Marti GE, Vogt RF, Shim YK, Middleton D, Landgren O.
Evolution of a precursor.
Cytometry B Clin Cytom. 78: 1-3, 2010.
[Journal]
81)  Goldin LR, Landgren O, Marti GE, Caporaso NE.
Familial Aspects of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and Related Lymphomas.
European journal of clinical & medical oncology. 2: 119-126, 2010.
[Journal]
82)  Quinlan SC, Landgren O, Morton LM, Engels EA.
Hodgkin lymphoma among US solid organ transplant recipients.
Transplantation. 90: 1011-5, 2010.
[Journal]
83)  Kristinsson SY, Koshiol J, Björkholm M, Goldin LR, McMaster ML, Turesson I, Landgren O.
Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia.
J. Natl. Cancer Inst. 102: 557-67, 2010.
[Journal]
84)  Engels EA, Pfeiffer RM, Landgren O, Moore RD.
Immunologic and virologic predictors of AIDS-related non-hodgkin lymphoma in the highly active antiretroviral therapy era.
J. Acquir. Immune Defic. Syndr. 54: 78-84, 2010.
[Journal]
85)  Quinlan SC, Morton LM, Pfeiffer RM, Anderson LA, Landgren O, Warren JL, Engels EA.
Increased risk for lymphoid and myeloid neoplasms in elderly solid-organ transplant recipients.
Cancer Epidemiol. Biomarkers Prev. 19: 1229-37, 2010.
[Journal]
86)  Mailankody S, Mena E, Yuan CM, Balakumaran A, Kuehl WM, Landgren O.
Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.
Leuk. Lymphoma. 51: 2159-70, 2010.
[Journal]
87)  Caporaso NE, Marti GE, Landgren O, Azzato E, Weinberg JB, Goldin L, Shanafelt T.
Monoclonal B cell lymphocytosis: clinical and population perspectives.
Cytometry B Clin Cytom. 78 Suppl 1: S115-9, 2010.
[Journal]
88)  Shanafelt TD, Ghia P, Lanasa MC, Landgren O, Rawstron AC.
Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management.
Leukemia. 24: 512-20, 2010.
[Journal]
89)  Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M.
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
Leukemia. 24: 1121-7, 2010.
[Journal]
90)  Kristinsson SY, Tang M, Pfeiffer RM, Björkholm M, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O.
Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study.
Blood. 116: 2651-5, 2010.
[Journal]
91)  Landgren O.
Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology.
Hematology Am Soc Hematol Educ Program. 2010: 295-302, 2010.
[Journal]
92)  Landgren O, Waxman AJ.
Multiple myeloma precursor disease.
JAMA. 304: 2397-404, 2010.
[Journal]
93)  Landgren O, Rajkumar SV, Pfeiffer RM, Kyle RA, Katzmann JA, Dispenzieri A, Cai Q, Goldin LR, Caporaso NE, Fraumeni JF, Blot WJ, Signorello LB.
Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women.
Blood. 116: 1056-9, 2010.
[Journal]
94)  Turesson I, Velez R, Kristinsson SY, Landgren O.
Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study.
J. Clin. Oncol. 28: 830-4, 2010.
[Journal]
95)  Turesson I, Velez R, Kristinsson SY, Landgren O.
Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic.
Mayo Clin. Proc. 85: 225-30, 2010.
[Journal]
96)  Shim YK, Middleton DC, Caporaso NE, Rachel JM, Landgren O, Abbasi F, Raveche ES, Rawstron AC, Orfao A, Marti GE, Vogt RF.
Prevalence of monoclonal B-cell lymphocytosis: a systematic review.
Cytometry B Clin Cytom. 78 Suppl 1: S10-8, 2010.
[Journal]
97)  McMaster ML, Landgren O.
Prevalence, clinical aspects, and natural history of IgM MGUS.
Cytometry B Clin Cytom. 78 Suppl 1: S91-7, 2010.
[Journal]
98)  Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Weiss BM, Kristinsson SY, McGlynn KA, Landgren O.
Racial disparities in incidence and outcome in multiple myeloma: a population-based study.
Blood. 116: 5501-6, 2010.
[Journal]
99)  Ma W, Kantarjian H, Zhang K, Zhang X, Wang X, Chen C, Donahue AC, Zhang Z, Yeh CH, O'Brien S, Garcia-Manero G, Caporaso N, Landgren O, Albitar M.
Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome.
BMC Med. Genet. 11: 163, 2010.
[Journal]
100)  Waxman AJ, Kuehl M, Balakumaran A, Weiss B, Landgren O.
Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future.
Clin Lymphoma Myeloma Leuk. 10: 248-57, 2010.
[Journal]
101)  Landgren O, Pfeiffer RM, Kristinsson SY, Björkholm M.
Survival patterns in patients with Hodgkin's lymphoma with a pre-existing hospital discharge diagnosis of autoimmune disease.
J. Clin. Oncol. 28: 5081-7, 2010.
[Journal]
102)  Andersson TM, Lambert PC, Derolf AR, Kristinsson SY, Eloranta S, Landgren O, Björkholm M, Dickman PW.
Temporal trends in the proportion cured among adults diagnosed with acute myeloid leukaemia in Sweden 1973-2001, a population-based study.
Br. J. Haematol. 148: 918-24, 2010.
[Journal]
103)  Landgren O.
A role for ionizing radiation in myelomagenesis?.
Blood. 113: 1616-7, 2009.
[Journal]
104)  Martin DN, Mikhail IS, Landgren O.
Autoimmunity and hematologic malignancies: associations and mechanisms.
Leuk. Lymphoma. 50: 541-50, 2009.
[Journal]
105)  Goldin LR, Landgren O.
Autoimmunity and lymphomagenesis.
Int. J. Cancer. 124: 1497-502, 2009.
[Journal]
106)  Kristinsson SY, Landgren O, Sjöberg J, Turesson I, Björkholm M, Goldin LR.
Autoimmunity and risk for Hodgkin's lymphoma by subtype.
Haematologica. 94: 1468-9, 2009.
[Journal]
107)  Landgren O, Albitar M, Ma W, Abbasi F, Hayes RB, Ghia P, Marti GE, Caporaso NE.
B-cell clones as early markers for chronic lymphocytic leukemia.
N. Engl. J. Med. 360: 659-67, 2009.
[Journal]
108)  Rusiecki JA, Patel R, Koutros S, Beane-Freeman L, Landgren O, Bonner MR, Coble J, Lubin J, Blair A, Hoppin JA, Alavanja MC.
Cancer incidence among pesticide applicators exposed to permethrin in the Agricultural Health Study.
Environ. Health Perspect. 117: 581-6, 2009.
[Journal]
109)  Anderson LA, Landgren O, Engels EA.
Common community acquired infections and subsequent risk of chronic lymphocytic leukaemia.
Br. J. Haematol. 147: 444-9, 2009.
[Journal]
110)  Liang XS, Caporaso N, McMaster ML, Ng D, Landgren O, Yeager M, Chanock S, Goldin LR.
Common genetic variants in candidate genes and risk of familial lymphoid malignancies.
Br. J. Haematol. 146: 418-23, 2009.
[Journal]
111)  Caporaso NE, Goldin LR, Anderson WF, Landgren O.
Current insight on trends, causes, and mechanisms of Hodgkin's lymphoma.
Cancer J. 15: 117-23, 2009.
[Journal]
112)  Goldin LR, Björkholm M, Kristinsson SY, Turesson I, Landgren O.
Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia.
Haematologica. 94: 647-53, 2009.
[Journal]
113)  Tsai HT, Caporaso NE, Kyle RA, Katzmann JA, Dispenzieri A, Hayes RB, Marti GE, Albitar M, Ghia P, Rajkumar SV, Landgren O.
Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study.
Blood. 114: 4928-32, 2009.
[Journal]
114)  Kristinsson SY, Goldin LR, Björkholm M, Koshiol J, Turesson I, Landgren O.
Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies.
Haematologica. 94: 1581-9, 2009.
[Journal]
115)  Kristinsson SY, Koshiol J, Goldin LR, Björkholm M, Turesson I, Gridley G, McMaster ML, Landgren O.
Genetics- and immune-related factors in the pathogenesis of lymphoplasmacytic lymphoma/ Waldenström's macroglobulinemia.
Clin Lymphoma Myeloma. 9: 23-6, 2009.
[Journal]
116)  Goldin LR, Björkholm M, Kristinsson SY, Samuelsson J, Landgren O.
Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms.
Genome Med. 1: 55, 2009.
[Journal]
117)  Goldin LR, Björkholm M, Kristinsson SY, Turesson I, Landgren O.
Highly increased familial risks for specific lymphoma subtypes.
Br. J. Haematol. 146: 91-4, 2009.
[Journal]
118)  Engels EA, Pfeiffer RM, Landgren O, Moore RD.
Immunologic and Virologic Predictors of AIDS-Related Non-Hodgkin Lymphoma in the Highly Active Antiretroviral Therapy Era.
Journal of acquired immune deficiency syndromes (1999). 2009.
[Journal]
119)  Kristinsson SY, Dickman PW, Wilson WH, Caporaso N, Björkholm M, Landgren O.
Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden.
Haematologica. 94: 1259-65, 2009.
[Journal]
120)  Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, Dispenzieri A, Kumar S, Clark RJ, Baris D, Hoover R, Rajkumar SV.
Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma: a prospective study.
Blood. 2009.
[Journal]
121)  McMaster ML, Kristinsson SY, Turesson I, Björkholm M, Landgren O.
Novel aspects pertaining to the relationship of Waldenström's macroglobulinemia, IgM monoclonal gammopathy of undetermined significance, polyclonal gammopathy, and hypoglobulinemia.
Clin Lymphoma Myeloma. 9: 19-22, 2009.
[Journal]
122)  Kristinsson SY, Landgren O, Rajkumar VS.
Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates.
Cancer J. 15: 473-8, 2009.
[Journal]
123)  Kristinsson SY, Björkholm M, Goldin LR, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O.
Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden.
Int. J. Cancer. 125: 2147-50, 2009.
[Journal]
124)  Landgren O, Weiss BM.
Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis.
Leukemia. 23: 1691-7, 2009.
[Journal]
125)  Kristinsson SY, Björkholm M, Andersson TM, Eloranta S, Dickman PW, Goldin LR, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O.
Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study.
Haematologica. 94: 1714-20, 2009.
[Journal]
126)  Landgren O, Kyle RA, Hoppin JA, Beane Freeman LE, Cerhan JR, Katzmann JA, Rajkumar SV, Alavanja MC.
Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study.
Blood. 113: 6386-91, 2009.
[Journal]
127)  Dores GM, Landgren O, McGlynn KA, Curtis RE, Linet MS, Devesa SS.
Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004.
Br. J. Haematol. 144: 86-94, 2009.
[Journal]
128)  Anderson LA, Gadalla S, Morton LM, Landgren O, Pfeiffer R, Warren JL, Berndt SI, Ricker W, Parsons R, Engels EA.
Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies.
Int. J. Cancer. 125: 398-405, 2009.
[Journal]
129)  Toro JR, Blake PW, Björkholm M, Kristinsson SY, Wang Z, Landgren O.
Prior history of non-melanoma skin cancer is associated with increased mortality in patients with chronic lymphocytic leukemia.
Haematologica. 94: 1460-4, 2009.
[Journal]
130)  Lidén Y, Landgren O, Arnér S, Sjölund KF, Johansson E.
Procedure-related pain among adult patients with hematologic malignancies.
Acta Anaesthesiol Scand. 53: 354-63, 2009.
[Journal]
131)  Landgren O, Dunleavy K, Wilson WH.
Re: Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.
J. Natl. Cancer Inst. 101: 1287-8; author reply 1289-90, 2009.
[Journal]
132)  Landgren O, Gilbert ES, Rizzo JD, Socie G, Banks PM, Sobocinski KA, Horowitz MM, Jaffe ES, Kingma DW, Travis LB, Flowers ME, Martin PJ, Deeg HJ, Curtis RE.
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.
Blood. 2009.
[Journal]
133)  El-Serag HB, Engels EA, Landgren O, Chiao E, Henderson L, Amaratunge HC, Giordano TP.
Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans.
Hepatology. 49: 116-23, 2009.
[Journal]
134)  Chiao EY, Engels EA, Kramer JR, Pietz K, Henderson L, Giordano TP, Landgren O.
Risk of immune thrombocytopenic purpura and autoimmune hemolytic anemia among 120 908 US veterans with hepatitis C virus infection.
Arch. Intern. Med. 169: 357-63, 2009.
[Journal]
135)  Landgren O, Kristinsson SY, Goldin LR, Caporaso NE, Blimark C, Mellqvist UH, Wahlin A, Bjorkholm M, Turesson I.
Risk of plasma-cell and lymphoproliferative disorders among 14,621 first-degree relatives of 4,458 patients with monoclonal gammopathy of undetermined significance (MGUS) in Sweden.
Blood. 2009.
[Journal]
136)  Kristinsson SY, Goldin LR, Björkholm M, Turesson I, Landgren O.
Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance.
Haematologica. 94: 1179-81, 2009.
[Journal]
137)  Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA.
Risks of myeloid malignancies in patients with autoimmune conditions.
Br. J. Cancer. 100: 822-8, 2009.
[Journal]
138)  Pfeiffer RM, Mitani A, Landgren O, Ekbom A, Kristinsson SY, Björkholm M, Biggar RJ, Brinton LA.
Timing of births and endometrial cancer risk in Swedish women.
Cancer Causes Control. 20: 1441-9, 2009.
[Journal]
139)  Koutros S, Baris D, Bell E, Zheng T, Zhang Y, Holford TR, Leaderer BP, Landgren O, Zahm SH.
Use of hair colouring products and risk of multiple myeloma among US women.
Occup Environ Med. 66: 68-70, 2009.
[Journal]
140)  Mellemkjaer L, Pfeiffer RM, Engels EA, Gridley G, Wheeler W, Hemminki K, Olsen JH, Dreyer L, Linet MS, Goldin LR, Landgren O.
Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma.
Arthritis Rheum. 58: 657-66, 2008.
[Journal]
141)  Koshiol J, Gridley G, Engels EA, McMaster ML, Landgren O.
Chronic immune stimulation and subsequent Waldenstrom macroglobulinemia.
Arch. Intern. Med. 168: 1903-9, 2008.
[Journal]
142)  Kristinsson SY, Fears TR, Gridley G, Turesson I, Mellqvist UH, Björkholm M, Landgren O.
Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma.
Blood. 112: 3582-6, 2008.
[Journal]
143)  Landgren O, Tilly H.
Epidemiology, pathology and treatment of non-follicular indolent lymphomas.
Leuk. Lymphoma. 49 Suppl 1: 35-42, 2008.
[Journal]
144)  Anderson LA, Pfeiffer R, Warren JL, Landgren O, Gadalla S, Berndt SI, Ricker W, Parsons R, Wheeler W, Engels EA.
Hematopoietic malignancies associated with viral and alcoholic hepatitis.
Cancer Epidemiol. Biomarkers Prev. 17: 3069-75, 2008.
[Journal]
145)  Derolf AR, Kristinsson SY, Andersson TM, Landgren O, Dickman PW, Bjorkholm M.
Improved patient survival for acute myeloid leukemia: A population-based study of 9,729 patients diagnosed in Sweden 1973-2005.
Blood. 2008.
[Journal]
146)  Gao Y, Kristinsson SY, Goldin LR, Björkholm M, Caporaso NE, Landgren O.
Increased Risk for Non-Hodgkin Lymphoma in Individuals with Celiac Disease and a Potential Familial Association.
Gastroenterology. 2008.
[Journal]
147)  Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Björkholm M.
Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
Blood. 112: 2199-204, 2008.
[Journal]
148)  Kristinsson SY, Björkholm M, Goldin LR, McMaster ML, Turesson I, Landgren O.
Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden.
Blood. 112: 3052-6, 2008.
[Journal]
149)  Brown LM, Gridley G, Check D, Landgren O.
Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders.
Blood. 111: 3388-94, 2008.
[Journal]
150)  McGlynn KA, Gridley G, Mellemkjaer L, Brinton LA, Anderson KC, Caporaso NE, Landgren O, Olsen JH.
Risks of cancer among a cohort of 23,935 men and women with osteoporosis.
Int. J. Cancer. 122: 1879-84, 2008.
[Journal]
151)  Gao Y, Linet MS, Gridley G, Mellemkjaer L, Hemminki K, Goldin LR, Landgren O.
Shared susceptibility for celiac disease and inflammatory bowel disease?.
Scand. J. Gastroenterol. 43: 1279-80, 2008.
[Journal]
152)  Rizzo JD, Curtis RE, Socie G, Sobocinski KA, Gilbert E, Landgren O, Travis LB, Travis WD, Flowers ME, Friedman DL, Horowitz MM, Wingard JR, Deeg HJ.
Solid cancers after allogeneic hematopoietic cell transplantation.
Blood. 2008.
[Journal]
153)  Anderson LA, Pfeiffer RM, Rapkin JS, Gridley G, Mellemkjaer L, Hemminki K, Björkholm M, Caporaso NE, Landgren O.
Survival patterns among lymphoma patients with a family history of lymphoma.
J. Clin. Oncol. 26: 4958-65, 2008.
[Journal]
154)  Landgren O, Gridley G, Check D, Caporaso NE, Morris Brown L.
Acquired immune-related and inflammatory conditions and subsequent chronic lymphocytic leukaemia.
Br. J. Haematol. 139: 791-8, 2007.
[Journal]
155)  Turesson I, Linet MS, Björkholm M, Kristinsson SY, Goldin LR, Caporaso NE, Landgren O.
Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003.
Int. J. Cancer. 121: 2260-6, 2007.
[Journal]
156)  Dunleavy K, Davis RE, Landgren O, Staudt LM, Wilson WH.
BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?.
Blood. 109: 843-4; discussion 844-5, 2007.
[Journal]
157)  Dores GM, Anderson WF, Curtis RE, Landgren O, Ostroumova E, Bluhm EC, Rabkin CS, Devesa SS, Linet MS.
Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology.
Br. J. Haematol. 139: 809-19, 2007.
[Journal]
158)  Caporaso N, Goldin L, Plass C, Calin G, Marti G, Bauer S, Raveche E, McMaster ML, Ng D, Landgren O, Slager S.
Chronic lymphocytic leukaemia genetics overview.
Br. J. Haematol. 139: 630-4, 2007.
[Journal]
159)  Linet MS, Schubauer-Berigan MK, Weisenburger DD, Richardson DB, Landgren O, Blair A, Silver S, Field RW, Caldwell G, Hatch M, Dores GM.
Chronic lymphocytic leukaemia: an overview of aetiology in light of recent developments in classification and pathogenesis.
Br. J. Haematol. 139: 672-86, 2007.
[Journal]
160)  Morton LM, Landgren O, Chatterjee N, Castenson D, Parsons R, Hoover RN, Engels EA.
Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients.
Blood. 110: 4599-605, 2007.
[Journal]
161)  Landgren O, Kyle RA.
Multiple myeloma, chronic lymphocytic leukaemia and associated precursor diseases.
Br. J. Haematol. 139: 717-23, 2007.
[Journal]
162)  Landgren O, Caporaso NE.
New aspects in descriptive, etiologic, and molecular epidemiology of Hodgkin's lymphoma.
Hematol. Oncol. Clin. North Am. 21: 825-40, 2007.
[Journal]
163)  Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Björkholm M.
Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003.
J. Clin. Oncol. 25: 1993-9, 2007.
[Journal]
164)  Landgren O, Katzmann JA, Hsing AW, Pfeiffer RM, Kyle RA, Yeboah ED, Biritwum RB, Tettey Y, Adjei AA, Larson DR, Dispenzieri A, Melton LJ, Goldin LR, McMaster ML, Caporaso NE, Rajkumar SV.
Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana.
Mayo Clin. Proc. 82: 1468-73, 2007.
[Journal]
165)  Landgren O, Rapkin JS, Caporaso NE, Mellemkjaer L, Gridley G, Goldin LR, Engels EA.
Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia.
Blood. 109: 2198-201, 2007.
[Journal]
166)  Landgren O, Turesson I, Gridley G, Caporaso NE.
Risk of malignant disease among 1525 adult male US Veterans with Gaucher disease.
Arch. Intern. Med. 167: 1189-94, 2007.
[Journal]
167)  Giordano TP, Henderson L, Landgren O, Chiao EY, Kramer JR, El-Serag H, Engels EA.
Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus.
JAMA. 297: 2010-7, 2007.
[Journal]
168)  Landgren O, Pfeiffer RM, Stewart L, Gridley G, Mellemkjaer L, Hemminki K, Goldin LR, Travis LB.
Risk of second malignant neoplasms among lymphoma patients with a family history of cancer.
Int. J. Cancer. 120: 1099-102, 2007.
[Journal]
169)  Landgren O, Axdorph U, Fears TR, Porwit-MacDonald A, Wedelin C, Björkholm M.
A population-based cohort study on early-stage Hodgkin lymphoma treated with radiotherapy alone: with special reference to older patients.
Ann. Oncol. 17: 1290-5, 2006.
[Journal]
170)  Landgren O, Engels EA, Pfeiffer RM, Gridley G, Mellemkjaer L, Olsen JH, Kerstann KF, Wheeler W, Hemminki K, Linet MS, Goldin LR.
Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia.
J. Natl. Cancer Inst. 98: 1321-30, 2006.
[Journal]
171)  Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K, Goldin LR.
Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study.
Int. J. Cancer. 118: 3095-8, 2006.
[Journal]
172)  Landgren O, Gridley G, Fears TR, Caporaso N.
Immune thrombocytopenic purpura does not exhibit a disparity in prevalence between African American and White veterans.
Blood. 108: 1111-2, 2006.
[Journal]
173)  Landgren O, Engels EA, Caporaso NE, Gridley G, Mellemkjaer L, Hemminki K, Linet MS, Goldin LR.
Patterns of autoimmunity and subsequent chronic lymphocytic leukemia in Nordic countries.
Blood. 108: 292-6, 2006.
[Journal]
174)  Landgren O, Björkholm M, Montgomery SM, Hjalgrim H, Sjöberg J, Goldin LR, Askling J.
Personal and family history of autoimmune diabetes mellitus and susceptibility to young-adult-onset Hodgkin lymphoma.
Int. J. Cancer. 118: 449-52, 2006.
[Journal]
175)  Cherif H, Landgren O, Konradsen HB, Kalin M, Björkholm M.
Poor antibody response to pneumococcal polysaccharide vaccination suggests increased susceptibility to pneumococcal infection in splenectomized patients with hematological diseases.
Vaccine. 24: 75-81, 2006.
[Journal]
176)  Landgren O, Rapkin JS, Mellemkjaer L, Gridley G, Goldin LR, Engels EA.
Respiratory tract infections in the pathway to multiple myeloma: a population-based study in Scandinavia.
Haematologica. 91: 1697-700, 2006.
[Journal]
177)  Johansson E, Engervall P, Landgren O, Grimfors G, Widell S, Rezai S, Björkholm M.
Response to splenectomy is durable after a certain point in time in adult patients with chronic immune thrombocytopenic purpura.
Eur. J. Haematol. 77: 61-6, 2006.
[Journal]
178)  Landgren O, Gridley G, Turesson I, Caporaso NE, Goldin LR, Baris D, Fears TR, Hoover RN, Linet MS.
Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States.
Blood. 107: 904-6, 2006.
[Journal]
179)  Landgren O, Zhang Y, Zahm SH, Inskip P, Zheng T, Baris D.
Risk of multiple myeloma following medication use and medical conditions: a case-control study in Connecticut women.
Cancer Epidemiol. Biomarkers Prev. 15: 2342-7, 2006.
[Journal]
180)  Goldin LR, Landgren O, McMaster ML, Gridley G, Hemminki K, Li X, Mellemkjaer L, Olsen JH, Linet MS.
Familial aggregation and heterogeneity of non-Hodgkin lymphoma in population-based samples.
Cancer Epidemiol. Biomarkers Prev. 14: 2402-6, 2005.
[Journal]
181)  Landgren O, Björkholm M, Granath F, Ekbom A.
Familial longevity: the older you are, the older your father may have been.
J Am Geriatr Soc. 53: 357-8, 2005.
[Journal]
182)  Björck E, Ek S, Landgren O, Jerkeman M, Ehinger M, Björkholm M, Borrebaeck CA, Porwit-MacDonald A, Nordenskjöld M.
High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma.
Blood. 105: 2908-15, 2005.
[Journal]
183)  Thelander EF, Walsh SH, Thorsélius M, Laurell A, Landgren O, Larsson C, Rosenquist R, Lagercrantz S.
Mantle cell lymphomas with clonal immunoglobulin V(H)3-21 gene rearrangements exhibit fewer genomic imbalances than mantle cell lymphomas utilizing other immunoglobulin V(H) genes.
Mod. Pathol. 18: 331-9, 2005.
[Journal]
184)  Landgren O, Kerstann KF, Gridley G, Mellemkjaer L, Hemminki K, Linet MS, Goldin LR.
Re: Familial clustering of Hodgkin lymphoma and multiple sclerosis.
J. Natl. Cancer Inst. 97: 543-4; author reply 544-5, 2005.
[Journal]
185)  Landgren O, Andrén H, Nilsson B, Ekbom A, Björkholm M.
Risk profile and outcome in Hodgkin's lymphoma: is obesity beneficial?.
Ann. Oncol. 16: 838-40, 2005.
[Journal]
186)  Landgren O, Porwit MacDonald A, Tani E, Czader M, Grimfors G, Skoog L, Ost A, Wedelin C, Axdorph U, Svedmyr E, Björkholm M.
A prospective comparison of fine-needle aspiration cytology and histopathology in the diagnosis and classification of lymphomas.
Hematol. J. 5: 69-76, 2004.
[Journal]
187)  Landgren O, Björkholm M, Konradsen HB, Söderqvist M, Nilsson B, Gustavsson A, Axdorph U, Kalin M, Grimfors G.
A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma.
J. Intern. Med. 255: 664-73, 2004.
[Journal]
188)  Osby E, Askling J, Landgren O, Dickman PW, Ekbom A, Björkholm M.
Parental longevity and prognosis in elderly patients with aggressive non-Hodgkin's lymphoma.
Acta Oncol. 43: 297-301, 2004.
[Journal]
189)  Landgren O, Algernon C, Axdorph U, Nilsson B, Wedelin C, Porwit-MacDonald A, Grimfors G, Björkholm M.
Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis.
Haematologica. 88: 438-44, 2003.
[Journal]
190)  Björck E, Landgren O, Schoumans J, Christensson B, Björkholm M, MacDonald AP, Nordenskjöld M.
Molecular cytogenetic approach to the diagnosis of splenic lymphoma: a case report of blastoid mantle cell lymphoma.
Leuk. Lymphoma. 44: 1229-34, 2003.
[Journal]
191)  Walsh SH, Thorsélius M, Johnson A, Söderberg O, Jerkeman M, Björck E, Eriksson I, Thunberg U, Landgren O, Ehinger M, Löfvenberg E, Wallman K, Enblad G, Sander B, Porwit-MacDonald A, Dictor M, Olofsson T, Sundström C, Roos G, Rosenquist R.
Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma.
Blood. 101: 4047-54, 2003.
[Journal]
192)  Landgren O, Askling J, Dickman PW, Osby E, Axdorph U, Ekbom A, Björkholm M.
Parental longevity and survival in elderly patients with Hodgkin's lymphoma.
Haematologica. 87: 596-601, 2002.
[Journal]
193)  Axdorph U, Sjöberg J, Grimfors G, Landgren O, Porwit-MacDonald A, Björkholm M.
Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease.
Ann. Oncol. 11: 1405-11, 2000.
[Journal]
194)  Landgren O, Axdorph U, Jacobsson H, Johansson B, Grimfors G, Björkholm M.
Routine bone scintigraphy is of limited value in the clinical assessment of untreated patients with Hodgkin's disease.
Med. Oncol. 17: 174-8, 2000.
[Journal]
195)  Landgren O.
Environmental pollution and delivery outcome in southern Sweden: a study with central registries.
Acta Paediatr. 85: 1361-4, 1996.
[Journal]
196)  Björkholm M, Axdorph U, Grimfors G, Merk K, Johansson B, Landgren O, Svedmyr E, Mellstedt H, Holm G.
Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease. A prospective randomized trial.
Ann. Oncol. 6: 895-9, 1995.
[Journal]
197)  Källén B, Landgren O.
Delivery outcome in pregnancies when either parent worked in the chemical industry. A study with central registries.
J Occup Med. 36: 563-8, 1994.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 4/16/2013.